IC
VIR icon

Inscription Capital’s Vir Biotechnology VIR Stock Holding History

Inscription Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Hold
11,715
– – 0.01% 761
2026
Q1 		$105K Buy
11,715
+402
+4% +$3.2K 0.01% 679
2025
Q4 		$68.2K Buy
+11,313
New +$67.4K 0.01% 672

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Inscription Capital's VIR Position: Q2 2026 in Review

Inscription Capital held its Vir Biotechnology (VIR) position steady in Q2 2026 at 11,715 shares worth $119K. The position accounts for 0.01% of the portfolio, ranked #761.

Inscription Capital first reported a position in VIR in Q4 2025 and has held it in 3 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Inscription Capital held 11,715 shares of Vir Biotechnology worth $119K as of Q2 2026.
  • Inscription Capital left its Vir Biotechnology share count unchanged in Q2 2026.
  • Vir Biotechnology made up 0.01% of Inscription Capital's portfolio in Q2 2026, its #761 holding.
  • Inscription Capital first reported a position in Vir Biotechnology in Q4 2025 and has held it in 3 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.